drugset / Trial / NCT04046016
A Study Using Whole-body PET After Oral Microdose of 18F-labeled Liporaxel in Patients With Solid Tumor
NaSingle-groupOpen-labelTreatment
Summary
An open-label, single oral dose of therapeutic Liporaxel and microdose 18F-Liporaxel administration study was conducted in two breast cancer patients. Therapeutic dose of Liporaxel was 200 mg/m2 and 18F-Liporaxel was 0.98-2.9 μg (185-555 MBq).
Timeline
- Start
- 2018-07-03
- Primary completion
- 2018-12-24
- Completion
- 2018-12-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Paclitaxel | Small molecule | 0.98 ug | Oral |
| Subject | Paclitaxel | Small molecule | 2.9 ug | Oral |
| Subject | Paclitaxel | Small molecule | 185 mbq | Oral |
| Subject | Paclitaxel | Small molecule | 200 mg/m2 | Oral |
| Subject | Paclitaxel | Small molecule | 300 mg | Oral |
| Subject | Paclitaxel | Small molecule | 555 mbq | Oral |